Generate:Biomedicines has announced the largest Series C for a biotech company in 2023 at $273 million, bringing their total equity financing since 2020 to nearly $700 million. The Series C funding will support the company in advancing their entire pipeline of 17 existing programs, largely focused on three different therapeutic areas: immunology, infectious disease, and oncology.